

Author Index

- A**
Adelman, K, 33
Almouzni, G, 297
Amon, A, 93, 299
- B**
Bartman, CR, 207
Benardallah, NS, 45
Benke, A, 9
Bernardi, G, 83
Bickmore, WA, 45
Blanco, MG, 103
Blobel, GA, 207
Brennecke, J, 302
Brunet, A, 275
- C**
Chan, CS, 139
Chan, YW, 103
Charpentier, E, 305
Coleman, RH, 1
Curie, T, 223
- D**
Darzacq, X, 1
Dekker, J, 308
Delahaye, C, 177
de Lange, T, 311
Demarque, M, 223
Dileep, V, 53
Doudna, J, 314
Downes, M, 249
Duboule, D, 9, 316
Dudgeon, C, 139
- E**
Emmenegger, Y, 223
Evans, RM, 249, 318
- F**
Fabre, PJ, 9
Fang, B, 233
Farley, EK, 27
- G**
Gaume, X, 165
Gerber, A, 223
Gilbert, DM, 53
Glass, CK, 213
Gonzales, KAU, 189
Gos, P, 223
Gosselin, D, 213
Gosselin, P, 223
Gotic, I, 223
Gray, D, 177
- H**
Hah, N, 249
Hainaut, P, 139
Harel I, 275
Heard, E, 324
Huang, W, 257
- I**
Ishii, H, 65
- J**
Jaenisch, R, 199
Johnson, AD, 265
- K**
Kadonaga, JT, 65
Khuong, MT, 65
Kingsley, D, 327
Knowles, BB, 155
Kurimoto, K, 147
- L**
Lazar, MA, 233
Leseva, M, 155
Levine, AJ, 139, 330
Levine, MS, 27
- Lin, KW, 111**
Lindquist, S, 332
Link, VM, 213
Lionnet, T, 1
Littman, DR, 257, 334
Liu, Z, 1
Loft, A, 239
- M**
Macrae, R, 302, 305, 308, 338, 340, 342
Mandrup, S, 239
Manley, S, 9
Matos, J, 103
Messerschmidt, DM, 155
Misteli, T, 73
Morimoto, R, 336
- N**
Ng, H-H, 189
Nocedal, I, 265
Noon, A, 177
- O**
Olson, KM, 27
- P**
Page, D, 338
Pegoraro, G, 73
Pellman, D, 117
Pfau, SL, 93
Puzio-Kuter, A, 139
- R**
Rando, G, 223
Reik, W, 340
Ren, B, 17, 342
Riddihough, G, 299, 311, 324, 348
Rivera-Mulia, JC, 53
- S**
Saini, C, 223
Saitou, M, 147
- Sarbajna, S, 103
Schibler, U, 223, 344
Schmidt, SF, 239
Scruggs, BS, 33
Sever, R, 318, 332, 353
Shachar, S, 73
Sherman, MH, 249
Sima, J, 53
Singer, RH, 1
Sinturel, F, 223
Skarnes, WC, 177
Solter, D, 155, 346
Steltzer, Y, 199
Strogantsev, R, 177
Svante, Pääbo, S, 291
- T**
Takahashi, N, 177
Tan, J, 316, 336, 346
Tarakhovskiy, A, 348
Tate, PH, 177
Tjian, R, 1
Torres-Padilla, M-E, 165
Trono, D, 281
- W**
West, SC, 103
Witkowski, Jan, 314, 321, 327, 330, 334
Wyatt, HDM, 103
Wysocka, J, 351
- Y**
Young, R, 353
Yu, RT, 249
Yue, F, 17
- Z**
Zakian, VA, 111
Zhang, C-Z, 117
Zlutorynski, E, 297, 344, 351

Subject Index

A

- ACF, 65–70, 72
ACTB, 76
AD. *See* Alzheimer's disease
Adipocyte
 genome-wide studies of formation and function, 239
 rosiglitazone modulation of genomic programming
 browning of human adipocytes, 241–243
 mature adipocyte studies, 240–241
 transcription factor cooperativity in adipogenesis, 239–240
 tumor necrosis factor–induced inflammation, 243–245
African turquoise killfish
 advantages as laboratory model, 275–276
 CRISPR/Cas9 genome editing, 276, 278
 prospects for aging studies, 278
 telomerase knockout and human pathologies, 276–278
Aging
 African turquoise killfish model. *See* African turquoise killfish
 overview of models, 275
Ahp11, 113
AID, 150
AID, 181
Alzheimer's disease (AD)
 monocyte enhancer studies, 218
 yeast studies, 332
Aneuploidy
 adoptive transfer for aneuploid hematopoietic malignancy studies, 99
 backcrossing and trisomic embryo fitness reduction, 96–98
 cancer, 300–301
 Down syndrome, hematopoiesis and mouse models, 98–99
 hematopoietic stem cells
 reconstitution for in vivo studies, 93–95
 Robertsonian chromosomes for aneuploidy generation, 95–96
AP-1, 214, 250
APOBEC, 119, 123, 150
APOBEC3B, 119
APOE, 276
Arg80, 270
ARID1A, 193
ASF-1, 298
ATM, 312
ATR, 312
ATRX, 167, 325

B

- β-Catenin, epiblast competence for germ cell fate, 150

- BFB cycle. *See* Breakage–fusion–bridge cycle
BLIMP1, 152, 155
Blimp1, 147, 149–152
BLM, 106
BMAL1, 224–225, 228–231
BMP4, 149–150
BRCA1, 120
BRCA2, 120
BRD4, 250
BRD4, 353
Breakage–fusion–bridge (BFB) cycle,
 dicentric chromosomal
 bridge resolution, 128–130
Breast cancer, kataegis, 123

C

- CAR, 250
CBP, 241, 353
CCND1, 130
Cdc5, 104
Cdc13, 112
Cdc28, 104
Cdc48, telomere length regulation, 113–114
CDH1, 114
Cdk6, expression in thymic lymphoma in p53 knockout mouse, 141–143
C/EBP, 214
C/EBPα, 239–241, 243, 245
CENP-A, 297
Chd1, 65, 68–69, 72
Chromatin
 chromosome looping model, 47–48
 regulation within nuclear domains, 48–49
Chromoanaysynthesis, patterns and mechanisms, 126–127
Chromoplexy, patterns and mechanisms, 127–128
Chromosomal rearrangements, global patterns, 120–123
Chromothripsis, patterns and mechanisms, 125–126
Circadian oscillators
 clock genes and synchronization in mammals, 224–225
 driven versus self-sustained oscillators, 229, 231
 liver circadian transcription. *See* Rev-erba
 suprachiasmatic nucleus, 224–227, 231, 344–345
 systematic timing clues
 body temperature and actin dynamics, 227–229
 feeding, 226
 glucocorticoid hormones, 226–227
CIRP, 228
CLOCK, 224, 228–229
CNV. *See* Copy number variation
COL1A1, 75–76

- COP9, 190
Copy number variation (CNV)
 global patterns, 120–123
 thymic lymphoma in p53 knockout mouse, 140–142
CpG islands. *See* Epigenetics
CREB, 224, 250
CRISPR/Cas9
 African turquoise killfish studies, 276, 278
 functional characterization of annotated enhancers, 20
 high-throughput functional screening, 194
 mechanism of action, 305–307, 314–315
 reporter generation for transcription imaging, 5
CRY, 224, 229–231
CTC1, 11
CTCF, 49, 84–89, 208–209, 353–354
Cx3cr1, 216
Cyclin D, expression in thymic lymphoma in p53 knockout mouse, 141–143

D

- DDX5, 259–262
DENND2C, 193
DHFR, 129
Dio3, 178
Dlk1, 178
DNA methylation. *See* Epigenetics
dNLP, 66–67, 69
DNMT1, 150, 158
Dnmt1, 199
Dnmt1, 178, 181
Dnmt3, 199
Dnmt3a, 201
Dnmt3a, 177–178, 181
Dnmt3b, 201
Dnmt3b, 177, 181
Dnmt3l, 177–178
Down syndrome (DS), hematopoiesis and mouse models, 98–99
DS. *See* Down syndrome
DSIF, 33–34
Dyskeratosis congenita, 312

E

- Elongation, transcription
 noncoding RNA regulation, 36–38
 overview, 33–34
Embryonic stem cell. *See* Pluripotency
EME1, 103–105
Enhancer
 activation, 17–18
 chromosome looping model, 47–48
 Ciona intestinalis studies of tissue specificity of developmental enhancer

Enhancer (*Continued*)

Otx-a enhancer optimization and loss of tissue specificity, 30
overview, 27–28
prospects for study, 31–32
suboptimal affinity binding sites for restricted expression, 28
suboptimal spacing of linked sites in endogenous enhancer, 29–30
trade-offs
binding affinities and syntax, 30–31
gene expression levels and specificity, 30
cis-acting elements, 46
DNA variations and consequences, 22–23
functional characterization of annotated enhancers, 20
functional overview, 17, 342–343
genomic methylation analysis, 203
hypomethylation of DNA, 19–20
identification in genome, 17–20
macrophage-specific enhancer studies
active enhancers and transcription initiation, 215–216
clinical significance, 217–218
de novo/latent enhancers, 215
environmental signals, cell identity, and enhancer repertoire, 216–217
epigenetics and genome-wide association studies, 217
model for selection and activation, 214–215
overview, 213–214
prospects for study, 218–219
promoter loops
chromatin structure probing, 209–210
linking and tracking of promoter communication, 46–47
Rev-erb α circadian enhancers, 234–235
super-enhancer, 353–354
SV40, 45
target gene selection for activation, 20–22

EPASI, 294

Epigenetics. *See also* Genomic imprinting; Histones

DNA methylation
CpG islands at transcription start sites, 36
dynamics in methylation imprinting, 177–181
genomic sequence analysis enhancers, 203
imprinted methylation regions, 203
promoters, 202–203
overview, 199
techniques for study, 200–201
traceable readout of endogenous DNA methylation state, 201–204

genome-wide DNA demethylation during germ cell development, 150–151, 178

hepatic stellate cell epigenetic reprogramming in liver fibrosis, 250–251

replication timing stability, 56
reprogramming during mammalian reproductive cycle
induced pluripotent stem cell formation, 171
overview, 155–156
postfertilization, 168–170
somatic cell nuclear transfer, 170
TRIM28
functional overview, 156–158
genomic imprinting role, 158–159
retrotransposon regulation, 159–160
ERBB2, 128–129
ESET, 157, 167
ESET, 181
Esrrb, 190
Est1, telomerase regulation, 112–113
Est3, 111–112, 114
ETS, 28–32, 250, 318
EZH2, 349

F

Fbxw, 193
FCS. *See* Fluorescence correlation spectroscopy
FGF. *See* Fibroblast growth factor
Fibroblast growth factor (FGF), 27, 30–32
FISH. *See* Fluorescence in situ hybridization
Fluorescence correlation spectroscopy (FCS), overview, 1–2
Fluorescence recovery after photobleaching (FRAP)
nascent transcription site imaging, 4
overview, 1–2
Fluorescence in situ hybridization (FISH)
chromosome looping model, 47–48
hiFISH, 74–75
HoxD cluster spatial segregation imaging, 10, 12, 14
nascent transcription site imaging, 4
FRAP. *See* Fluorescence recovery after photobleaching
FXR, 250

G

GATA, 27–30
GATA6, 216
GEN1, 104, 106–108
Genomic imprinting
TRIM28 role, 158–159
knockout mouse studies of methylation imprints, 179–180
KRAB domain zinc finger proteins, 181
ZFP57
functional overview, 184
genomic imprinting role, 181–185, 321
Glucocorticoid receptor (GR), 226, 243
GR. *See* Glucocorticoid receptor
GSK3, 193

H

H19, 178, 181–182
HDAC3, 233, 237
Heat shock response, 336–337
Hematopoietic stem cell. *See* Aneuploidy

Hepatic stellate cell (HSC)
epigenetic reprogramming in liver fibrosis, 250–251
overview, 249
Hi-C
enhancer target gene selection for activation, 21–22
HoxD cluster topologically associating domain visualization, 10–11
High-throughput functional screening (HTFS)
CRISPR/Cas9, 194
in vivo, 195
organoids, 195
High-throughput imaging. *See* HIPMap
HIPMap
automated imaging, 75
chromosome break and translocation determination, 78–79
chromosome conformation capture data validation, 78
data analysis, 75–76
gene position
change detection, 76–77
determination, 76
hiFISH, 74–75
image analysis, 75
immunofluorescence combination studies, 79
principles, 73–74
prospects, 80
quality control
false FISH signal detection, 76
minimal sample size, 76
robustness of measurements, 76
RNA FISH coupling, 80
RNA interference screening, 78
scale-up, 77–78
systematic mapping of three-dimensional imaging, 78
versatility, 76
Histones
epigenetic reprogramming during mammalian reproductive cycle
induced pluripotent stem cell formation, 171
overview, 155–156
postfertilization, 168–170
somatic cell nuclear transfer, 170
variants
H1, 166–167
H2A, 166
H3, 165–166
heterochromatin establishment and maintenance by variants, 167–168
plasticity program role, 171–172
HIV. *See* Human immunodeficiency virus
HJURP, 297
Holliday junction
dissolution, 103
processing defects and mitotic catastrophe, 106, 108
resolution
human cell studies
GEN1, 106–107
SLX-MUS complex, 105–106
overview, 103–104
yeast studies, 104–105
Hox, 316
Hoxa1, 150

- Hoxb1*, 150
HoxD cluster
 regulation overview, 9–10
 spatial segregation imaging, 10, 12
 stochastic optical reconstruction microscopy, 13–14
 topologically associating domains
 maximal chromatin elongation
 at boundary, 14–15
 visualization, 10–11
HP, 157
HSC. *See* Hepatic stellate cell
HSF1, 228
HTFS. *See* High-throughput functional screening
Human immunodeficiency virus (HIV), 207
HXX1, 208
- I**
IGF2, 158
Ikaros, expression in thymic lymphoma
 in p53 knockout mouse, 141–143
Induced pluripotent stem cell (iPSC),
 epigenetic reprogramming
 in formation, 171
INO80, 190
Interphase
 chromosome structure and architecture,
 84–85
 interphase chromatin to prophase
 bands, 85–88
 metaphase to interphase bands, 88
iPSC. *See* Induced pluripotent stem cell
IRF, 214
- K**
KAP1, 181
KAP1, 282, 284–286
Kataegis, patterns and mechanisms,
 123–125
KDM1B, 177–178
KLF4, 152
KLF11, 242–243
KRAB domain zinc finger proteins. *See*
 also TRIM28
 adult human cell expression and gene
 expression modulation,
 283–285
 embryogenesis role, 282–283
 genomic imprinting role, 181
 prospects for transposon control studies,
 285–287
 transposon early embryonic repression,
 282
- L**
LADF, 75–77, 79
LADs. *See* Lamina-associated domains
Lamina-associated domains (LADs),
 207–208, 210
Lamins, 75–76
LCR. *See* Locus control region
Ldb1, 209
LDTFs. *See* Lineage-determining
 transcription factors
Li–Fraumeni syndrome, 139, 330
Lineage-determining transcription factors
 (LDTFs), 214–215
- Lipopolysaccharide (LPS), 37
Liver fibrosis. *See* Hepatic stellate cell
Locus control region (LCR), 45
LPS. *See* Lipopolysaccharide
LRRK2, 333
LXR, 214
- M**
Mcm1, 270
MDM2, 143
MED1, 241, 244
Meiotic sex chromosome inactivation
 (MSCI), 168
MEK, 193
Metaphase
 metaphase to interphase bands, 88
 prophase chromatin to metaphase
 bands, 88
MIXL1, 152
MMP9, 76
Mmp9, 216
MPE-seq, prenucleosome localization
 upstream of active
 promoters, 70–71
Mre11, 112
MRT-2, 129
MRTF, 229
MSCI. *See* Meiotic sex chromosome
 inactivation
MUS81, 103–106
MusD, 159–160
MyoD, 250
- N**
Nanog, 190, 193
Nanog, 148, 171
NANOS3, 152
NAP1, 65–66, 68–69
NCoR, 216, 233, 237
Neanderthals, 291–94
NELF, 33–34
Nespas, 182
NF- κ B. *See* Nuclear factor- κ B
Nfe2, 194
NFRKB, 190
Nobox, 194
Npl4, 113
Nr5a1, 192
Nr5a2, 192
Nuclear factor- κ B (NF- κ B), 39, 214–215,
 244, 250
Nuclear radial positioning, 207–208
Nucleosome. *See* Prenucleosome
NuRD, 157, 181
- O**
Oct4, 190, 193
Oct4, 171
Otx-a enhancer. *See* Enhancer
- P**
p53
 germline mutations in humans, 143
 Li–Fraumeni syndrome mutations,
 139, 330–331
 thymic lymphoma in knockout mouse
 copy number variation, 140–142,
 145
DNA extraction and TCR- β
 sequencing, 144
pathogenesis, 140
western blotting, 145
whole-exome sequencing, 140,
 144–145
 tumor mutations, 139–140, 143
Pancreatic stellate cell (PSC)
 overview, 249–250
 transcriptional and epigenetic
 regulation of pancreatic
 tumor microenvironment,
 251–252
Parkinson’s disease (PD), yeast studies,
 332–333
PARP-1, 226
PBAF, 193
PD. *See* Parkinson’s disease
Pdrm1, 147
Pdrm14, 148–151
Peg1, 181
Peg3, 181–182
Peg10, 181
PER, 224, 229–231
PGC. *See* Primordial germ cell
PGC7, 181
PHO5, 68
PITX1, 328–329
PITX2, 329
PIWI-interacting RNA, 302–304
PLAGL1, 182
PLK1, 105
Pluripotency
 cell models, 189–190
 embryonic stem cell
 modeling of pluripotency, 194
 replication timing, 56
 reprogramming, 347
 experimental strategies
 overview, 129, 131
 single-cell mutations
 detection, 131–132
 sequencing, 132–133
 global patterns, 117–120
 high-throughput functional screening
 CRISPR/Cas9, 194
 in vivo, 195
 organoids, 195
 induced pluripotent stem cells and
 epigenetic reprogramming
 in formation, 171
 molecular dissection
 dissolution of pluripotency,
 192–193
 induction of pluripotency,
 190–192
 maintenance of pluripotency,
 190
 molecular networks, 193–194
 Point mutations
 POLD3, 127
 Pou5f1, 148
 POU1F1, 192
 PPAR γ , 239–245
 PRDM14, 190
 Prenucleosome
 discovery, 65–68
 formation, 66–68
 functions in active chromatin, 72
 localization upstream of active
 promoters, 70
 promoter association, 68
 prospects for study, 70–71
 stability, 67, 69–70

- Primordial germ cell (PGC)
chromatin remodeling during germ cell development, 151–152, 340–341
development in mice, 147–148
differentiation, 147
epiblast competence for germ cell fate, 150
genome-wide DNA demethylation during germ cell development, 150–151
human primordial germ cell-like cell induction, 152–153
reconstitution in culture of mouse cells
primordial germ cell-like cell reconstitution by induced transcription factors, 149–150
specification pathway, 149
Promoter. *See* Enhancer; Transcription start site
Prophase
interphase chromatin to prophase bands, 85–88
prophase chromatin to metaphase bands, 88
PSC. *See* Pancreatic stellate cell
P-TEFb, 34, 41
PTEN, 331
Pten, expression in thymic lymphoma in p53 knockout mouse, 141–143
Pten, 141
PU.1, 40–41, 214–216
PXR, 250
- R**
Rad50, 112
Rarb, 217
Rasgrf1, 178, 181–182
RELA, 244
Replication timing (RT)
chromomeric banding patterns, 56
chromosomal unit regulation, 56–57
constant timing region, 54
constitutive versus switching replication domains, 57–58
gene expression relationship, 58–60
genome-wide measurement, 54
overview, 53
replication origin identification, 54–55
resolution of profiling data, 55–56
stability, 56
timing transition region, 54
topologically associating domain formation, 57
replication domain model, 57, 60
Retinoic acid–related orphan receptors (RORs)
liver circadian transcription regulation, 235–236
ROR γ t regulation of Th17 cell differentiation, 259–261, 335
REV-ERB α , 224
Rev-erb α
Bmal1/Clock feedback loop, 233
circadian enhancers, 234–235
clock coordination with retinoic acid–related orphan receptors, 235–236
DNA binding, 233
lipid metabolic gene regulation through active repression, 236
prospects for study, 236–237
REV-ERB β , 224, 229
RhoA, 229
Rmrp, 260–262
RNA polymerase II, 34–35, 38–39, 41–42, 46, 210
Robertsonian chromosome, aneuploidy generation in hematopoietic stem cells, 95–96
RORs. *See* Retinoic acid–related orphan receptors
Rosiglitazone, modulation of genomic programming in adipocytes
mature adipocyte studies, 240–241
browning of human adipocytes, 241–243
RT. *See* Replication timing
RUNX, 250
- S**
SAA. *See* Serum amyloid A
SCN. *See* Suprachiasmatic nucleus
SCNT. *See* Somatic cell nuclear transfer
SDTF, 215–216
Serum amyloid A (SAA), regulation of Th17 cell effector responses, 258–259, 335
SETDB1, 285
SETDB1, 181
Sex chromosomes, 338–339
SGBS. *See* Simpson–Golabi–Bemel syndrome
Shh. *See* Sonic hedgehog
SIM. *See* Structured illumination microscopy
Simpson–Golabi–Bemel syndrome (SGBS), 243
Single-particle tracking (SPT), overview, 2
SIRT1, 226
SLC16A11, 293
SLX-MUS complex, 105–106
SLX1, 103, 105–106
SLX4, 103, 105–106, 108
SMARCC1, 194
SMARCC2, 194
Snai1, 193–194
Snai2, 193–194
Snrpn, 181–182
Somatic cell nuclear transfer (SCNT), epigenetic reprogramming, 170
Sonic hedgehog (Shh), 31–32
SOX17, 152
Sox2, 20, 190
Sox2, 148, 171
SPT. *See* Single-particle tracking
SRF, 229
SSETDB1, 157
Stellate ell. *See* Hepatic stellate cell; Pancreatic stellate cell
STN1, 111
Stochastic optical reconstruction microscopy (STORM)
HoxD cluster studies, 13–15
telomere end studies, 312
STORM. *See* Stochastic optical reconstruction microscopy
Structured illumination microscopy (SIM)
overview, 1–2
prospects for transcription imaging, 5
Suprachiasmatic nucleus (SCN), 224–227, 231, 344–345
SWI/SNF, 353
- T**
TAD. *See* Topologically associating domain
TBP, 36, 39, 46s
Tbx3, 190
TCAB1, 111–115
Tcf3, 193
Tcl1, 190
TCL1B, 152
TDG, 150
TDP-43, 332–333
Telomerase
African turquoise killfish knockout studies, 276–278
associated proteins, 113
cell cycle regulation, 112, 114
isolation from yeast, 112–113
mass spectrometry studies of components, 111–114
prospects for study, 114–115
subunits, 111–112
telomere length regulation by associated proteins
Cdc48 complex, 113–114
UFD4, 114
TEN1, 111
TET1, 150–151
Tet1, 181–182
Tet3, 181
TF. *See* Transcription factor
Tjap2c, 149–152
TGF- β . *See* Transforming growth factor- β
Th17 cell
autoimmune disease therapeutic targeting, 261–262
cytokines, 257
functional overview, 257
prospects for study, 262
ROR γ t regulation of cell differentiation, 259–261
segmented filamentous bacteria in induction, 257–258, 334–335
serum amyloid A regulation of effector responses, 258–259, 335
TH2, 209
TH2A, 169–171
TH2B, 169–171
T-helper cell. *See* Th17 cell
TLC1, 111–112
TLR4, 215
TNAP, 152
TNF. *See* Tumor necrosis factor
Topologically associating domain (TAD)
chromatin structure probing, 208–209
dynamics, 210
enhancer target gene selection for activation, 22
HoxD cluster
maximal chromatin elongation at boundary, 14–15
visualization, 10–11
overview, 308–309
replication timing formation, 57
replication domain model, 57, 60
Transcription factor (TF)
live-cell imaging of dynamics, 2–3
single-particle tracking, 2
Transcription network rewiring
biological novelty generation
gene duplication, 271–273

- intercalation of a regulator, 271
 - constraints
 - duplicated transcription regulators, 268, 270–271
 - intersecting networks, 268
 - output preservation, 266–268
 - overview, 265–266
 - prospects for study, 273
 - Transcription start site (TSS)
 - CpG islands, 36
 - divergent promoters, 36, 39–42
 - genomic methylation analysis of promoters, 202–203
 - location of antisense start sites, 39–40
 - noncoding RNA regulation, 36, 39
 - promoter elements, 34–35
 - sequence analysis, 35
 - transcription factor interactions, 33
 - Transforming growth factor- β (TGF- β), 250, 258, 331
 - Transposon
 - adult human cell expression and gene expression modulation, 283–285
 - embryogenesis role, 282–283
 - functional overview, 281–282
 - KRAB domain zinc finger proteins
 - early embryonic repression, 282
 - prospects for transposon control studies, 285–287
 - TRIM28 in retrotransposon regulation, 159–160
 - TREX1, 126–127
 - TRF2, 126, 312
 - TRIM28
 - functional overview, 156–158
 - genomic imprinting role, 158–159
 - retrotransposon regulation, 159–160
 - Trp53, 119
 - TRRAP*, 193
 - Trt1, 115
 - TSS. *See* Transcription start site
 - Tumor necrosis factor (TNF),
 - inflammation induction in adipocytes, 243–245
- U**
- U1, 37–38
 - UCP1, 233
 - Ufd1, 113
 - UFD4, telomere length regulation, 114
 - Uhrf1*, 150
- V**
- VDR. *See* Vitamin D receptor
 - VEGF*, 76
 - Vitamin D analogs, cancer prevention studies, 252–253, 319–320
 - Vitamin D receptor (VDR), 243, 250–251, 253, 318–319
- W**
- WHOA, 193
 - WNT, epiblast competence for germ cell fate, 150
 - WNT3, 150
- X**
- XIST, 324–326
 - XPF, 105
 - Xrs2, 112
- Y**
- Yen1, 104–105
- Z**
- Zac1*, 182
 - ZFP57*
 - functional overview, 184
 - genomic imprinting role, 181–185, 321
 - ZFP57*, 181–182
 - ZFP809*, 181
 - ZGA. *See* Zygote genome activation
 - ZicL, 31
 - ZNF91*, 181
 - ZNF93*, 181
 - Zygote genome activation (ZGA), 168, 170